Philips & the U.S. Department of Defense Develop Breakthrough Technology Using AI to Identify Infection More Than 48 Hours Be...
October 22 2019 - 9:00AM
Business Wire
Using large data sets & machine learning across biomarkers,
innovative tech can speed time to detection, intervention &
treatment, while improving outcomes & reducing spread of
disease
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health
technology, the Defense Threat Reduction Agency (DTRA), and Defense
Innovation Unit (DIU) of the U.S. Department of Defense (DoD) today
announced highlights from an 18-month project in predictive health
monitoring aimed at developing an early warning algorithm to detect
infection before an individual shows signs or symptoms. The
project, Rapid Analysis of Threat Exposure (RATE), is the first
large-scale empirical exploration of prediction of pre-symptomatic
infection in humans and is part of efforts to improve readiness, as
well as being broadly applicable in healthcare settings. As
envisioned by DTRA, an early warning system that facilitates faster
diagnosis and treatment of infection can reduce individual downtime
and aid in quickly containing the spread of a communicable disease
by isolating exposed individuals sooner.
The prototype revealed that using artificial intelligence (AI)
to look at certain combinations of vital signs and other biomarkers
could strongly predict the likelihood of infection up to 48 hours
in advance of clinical suspicion, including observable symptoms. In
addition, it found that the combinations of significant vital signs
and biomarkers varied based on time before clinical suspicion of a
hospital acquired infection (HAI). Future research is currently
being planned to leverage this information as an algorithm to be
integrated into a wearable device, allowing a soldier’s health to
be non-invasively monitored and delivering earlier alerts to
potential infection. The technology could further be applied in a
civilian capacity by helping to monitor hospital patients for
infection prior to clinical symptoms.
“The unique capability that Philips has produced enables the
chemical and biological defense medical paradigm to shift from a
reactionary focused one to a predictive one. This provides our
commanders with insight into their troops’ future readiness levels
and can influence mission planning and overall military
effectiveness,” said Edward Argenta, Science and Technology Manager
for the Joint Science & Technology Office at DTRA.
Traditional approaches to diagnosing infections rely on
recognition of overt signs, which can mean implementing medical
countermeasures after active duty personnel have already been
compromised and potentially exposed others. Characterizing
pre-symptomatic sentinels indicative of infection using AI
mechanisms can help reduce time to diagnosis and treatment, but as
with any AI, this process requires a large reliable dataset.
Unlike other narrow attempts to predict human infection, the
RATE approach uses large-scale data machine learning and
trade-space analyses across 165 different biomarkers from a rich
Philips dataset of over 41,000 cases of HAIs. The dataset was
extracted from a large data repository of more than seven million
hospital patient encounters. The pared down cases were used as a
surrogate dataset for infection in otherwise healthy military
personnel and analyzed to develop a predictive algorithm of
disease. The performance of the algorithm to predict infection 48
hours before clinical suspicion can be characterized technically as
area-under-the-curve of 0.853. For comparison, this performance
lies in between blood-based breast and prostate cancer screening
tests and an enzyme immunoassay based first-tier Lyme disease
test.
“At Philips, we understand that large, reliable datasets are the
lifeblood of AI-based healthcare applications and we have been at
the forefront of creating them for the development of machine
learning in collaboration with our clinical and academic partners
for some time now,” said Dr. Joseph Frassica, chief medical officer
and head of research for Philips North America. “By coupling
large-scale data, with our experience in AI and remote patient
monitoring with DTRA’s drive for innovation, we were able to
develop a highly predictive early-warning algorithm based on
non-invasively collected biomarkers. While the RATE data is derived
from acute care settings, we believe that it is adaptable to active
duty personnel. These results can be extended in future work to
also apply to other healthcare settings, and to include scenarios
where vital signs and biomarkers fluctuate as a function of factors
such as physical exertion and heat stress.”
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2018
sales of EUR 18.1 billion and employs approximately 78,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
About Defense Threat Reduction Agency
The Defense Threat Reduction Agency enables DoD, the U.S.
Government and International Partners to counter and deter Weapons
of Mass Destruction and Improvised Threat Networks. DTRA is a
Combat Support Agency and a Defense Agency with a three-pronged
mission (1) to counter the threats posed by the full spectrum of
weapons of mass destruction (WMD), including chemical, biological,
radiological, nuclear, and high-yield explosives; (2) to counter
the threats posed by the growing, evolving categories of improvised
threats, including improvised explosive devices, car bombs and
weaponized consumer drones, as well as the tactics, technologies
and networks that put them on the battlefield; (3) to ensure the
U.S. military maintains a safe, secure, effective and credible
nuclear weapons deterrent. For more information visit
www.dtra.mil.
About Defense Innovation Unit
DIU strengthens our national security by increasing the adoption
of commercial technology throughout the military and growing the
national security innovation base. Learn more about portfolios and
projects at www.diu.mil.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191022005346/en/
Silvie Casanova Philips North America Tel.: +1-781-879-0692
E-mail: Silvie.casanova@philips.com
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Apr 2023 to Apr 2024